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Abstract 
Medical cannabis access has been shown to affect clinical health outcomes and health care spending. Unlike medical 
access, which requires a doctor's recommendation for treatment and only applies to the limited conditions approved 
under the state's medical cannabis program, recreational access makes cannabis available over-the-counter (OTC). 
This may create additional benefits through off-label cannabis use to treat unlisted conditions, such as acid reflux, 
which affects two out of three Americans. Using the roll out of recreational dispensaries in Colorado in 2014, we 
estimate the change in retailers' market share of antacid medications using a difference-in-differences design. Antacid 
market share decreases after a dispensary enters a county by 0.85 percentage points. Decreases come from histamine 
receptor antagonists and proton pump inhibitors. Decreased antacid use may occur through direct substitution for OTC 
antacids, through changes in dietary behaviors that reduce antacid use, or both. More work is needed to disentangle 
these two effects. 
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1. Introduction
Evidence is accumulating that medical access to cannabis affects clinical practice and health care
spending in the United States.  Bradford and Bradford (2016, 2017, 2018) find that after states
legalized access to medical cannabis dispensaries, use of prescription drugs for which cannabis
could serve as a clinical alternative fell. Decreases came from prescription drugs used on- and
off-label to treat anxiety disorders, depression and mood disorders, nausea, pain, psychosis, 
seizure disorders, sleep disorders, and spasticity for Medicaid and Medicare recipients.  Patient-
level studies document similar decreases in prescription drug use from medical cannabis access
(Stith et al., 2018a; Vigil et al., 2017).  Bradford and Bradford (2018) estimate Medicare
spending would decrease by $1.4-1.7 billion annually if all states allowed medical cannabis
access via dispensaries.
As states begin to legalize recreational access to cannabis, it begs the question: does recreational
access also bring clinical care and health care spending benefits? If recreational access facilitates
existing medical use, we would expect additional benefits to be small. However, benefits may be
much larger if recreational access eases off-label use to treat conditions not approved under state
medical cannabis programs, including less severe conditions or conditions with weaker evidence
from medical research.1 Medical cannabis requires that a clinical provider recommend the drug
if a patient presents with an illness listed on the state medical cannabis program (Klofas and
Leteney 2012).  Recreational dispensaries do not. To get a sense of the potential magnitude of
these benefits, consider prescription drugs, where a third of all prescriptions are off-label
(Bradford, Turner, and Williams 2018).
We investigate whether recreational access facilitates off-label use of cannabis for a particularly
widespread unlisted medical condition. Gastroesophageal reflux disease (GERD), also known as
acid reflux or heartburn, affects more than two thirds of Americans (Cohen et al., 2014) and in
2014 Americans spent $2.5 billion dollars on antacids (CHPA 2018). Among 33 state medical
cannabis program (plus DC), not one included GERD among their qualifying conditions for
medical cannabis use. 2 Using retail scanner data in a difference-in-differences design, we 
measure how the roll out of recreational dispensaries in Colorado affected sales of over-the-
counter (OTC) antacids.
In addition to its broad impact, we focus on GERD for two reasons.  First, cannabis may be a 
clinical alternative to OTC antacids to treat GERD. Though federal barriers in the United States
limit medical research (Stith and Vigil 2016), a European study found that, in both dogs and
humans, cannabis reduces meal-induced transient lower esophageal sphincter relaxations, the 
principle mechanism in GERD (Beaumont et al. 2009). Users self-report cannabis effectiveness
1 Medical access to cannabis has been shown to decrease cannabis prices (Anderson, Hansen and Rees 2013),
suggesting that medical cannabis is diverted into recreational markets.  Given this, we would expect treatment of
unlisted conditions to occur with medical access as well, primarily through two pathways: off-label use by medical
cannabis patients to treat unlisted conditions and self-treatment from cannabis purchased in the illegal market.
Recreational access would amplify the effects of each pathway.
2 Many states include nausea among their qualifying conditions, typically as arises from cancer treatment. Milder




   
 
   
      
  
  
    
      
     
    
  
    
   





     
   
   
        
 
    
 
   
  
   
 
                                                 
  
 
    
   
     
 
   
       
  
to treat symptoms associated with gastrointestinal distress, including nausea, lack of appetite,
and gastrointestinal pain (Stith et al, 2018b).  
Second, some OTC antacids carry significant risks, particularly for older adults, which could
allow for potential welfare gains.  The American Geriatrics Society recommends older adults
avoid antacids with histamine receptor antagonists (H2) and proton pump inhibitors (PPI) due to
concerns that they lower bone mineral density (Bahtiri et al. 2016), increase the risk of hip 
fractures (Adams et al. 2016), increase the risk of cognitive impairment (Gomm et al. 2016), and
increase the severity of Clostridium difficile infections (Stewart et al. 2013).3 
Our work highlights a new set of benefits from access to cannabis distinct to recreational
cannabis legalization: greater off-label cannabis use for conditions not approved under medical
access programs. While broader, social risks associated with recreational legalization are well-
documented (Anderson and Rees 2014), benefits to clinical care from off-label use are 
unrecognized. Yet they may be sizable. We focus on just one potential therapeutic use for
recreational cannabis, GERD, and our estimates suggest nationwide recreational access to
cannabis would have decreased 2014 OTC antacid market share by about 0.8 percentage points
or spending by about $267 million.
2. Methods
2.1. Data
Retail scanner data on antacids and over-the-counter medication come from Nielsen through the
Kilts Center for Marketing. Data include all monthly individual product sales for stores in the
Nielsen sample.4 The sample includes all stores in the Nielsen panel dataset between 1/2013 and 
12/2015.5 For our analysis by antacid drug type, we used online manufacturer descriptions to
identify active ingredients and group products into three categories: two types of acid blockers,
H2 and PPI, and acid neutralizers (calcium-, aluminum-, or magnesium-based formulates). 
Recreational dispensary zip code data come from the Colorado Department of Revenue and were
matched to counties using the United States Department of Housing and Urban Development's
zip code-county crosswalk for the first quarter of 2014. Medical cannabis patient information is
from the Colorado Department of Public Health’s Medical Cannabis Registry and county-level
population data are from U.S. Census Bureau.
3 Risks to older adults from cannabis are poorly understood, however, one study found older users employed 
strategies to reduce cannabis harms (Lau et al. 2015).
4 Researchers own analyses calculated (or derived) based in part on data from The Nielsen Company (US), LLC and
marketing databases provided through the Nielsen Datasets at the Kilts Center for Marketing Data Center at The 
University of Chicago Booth School of Business.
5 Note, our panel is not balanced: stores enter and exit the Nielsen panel between 2013 and 2015. The average 
number of observations per store is 34.7.  136 stores out of 746 stores have fewer then 36 store-months during this
time period. In our regressions we included stores with fewer than 36 observations, giving us an unbalanced panel.






       
 
      
      
      
      
      
      
 
      
      
      
      
      
      
            
 
  
     
    
       
    
   




   




                                                 
  
 
Table I: Summary Statistics
N mean sd min max
Panel A: Store (746 Stores)
Units, antacids 24,860 348.1 301.3 3 2,475
Units, all OTC 24,860 2,519 2,138 23 19,690
Share, antacid 24,860 14.56 4.234 2.622 47.62
Rec Dispensary 24,860 0.545 0.498 0 1
Med Marijuana Share 24,860 2.095 0.668 0.505 5.151
Population 24,860 386,574 243,931 1,353 680,658
Panel B: Store-Drug Type (746 Stores, 2,238 Store-Drug Types)
Share, acid neutralizer 24,860 68.18 8.770 24.24 100
Share, H2 24,860 15.98 4.324 0 61.67
Share, PPI 24,860 15.84 7.479 0 66.67
Rec Dispensary 74,580 0.518 0.500 0 1
Med Marijuana Share 74,580 2.095 0.668 0.505 5.151
Population 74,580 386,574 243,928 1,353 680,658
2.2. Measures
Our outcome variable is monthly OTC antacid market share. Market share avoids scale effects
from store-level differences in aggregate demand. For our store analysis, we divide unit sales of
OTC antacids by unit sales of all OTC medications for each store for each month, giving one
observation per store-month. Average antacid market share over this period was 14.56%, as seen
in Table I. For our category analysis, we divide unit sales of each category of OTC antacids by
total unit sales for OTC antacids, giving three observations per store-month.6 Acid neutralizers’
market share is greatest, at 68% of total antacid sales. H2 and PPI market shares are similar, on
average, at about 16% each. 
Our treatment variable is county-level recreational cannabis access by month. We use the 
existence of any recreational dispensaries in that county-month. Cannabis became legally 
available for purchase without a doctor’s referral from dispensaries with recreational licenses as
early as 1/1/2014. As seen in Figure 1, dispensary access expanded in 2014, varying from 0, 
including some counties that banned the sale of recreational cannabis, to a maximum of 101 in
Denver County. 






    
  
       
       
    
  
     
   
   
     
     
  
 
   
   




Figure 1: Dispensary Rollout in Colorado in 2014 
2.3. Empirical Analysis
For our difference-in-differences estimator, we use the following regression specification:�ℎ����� = � + ����� + ���� + �� + �� + ��� (1)
where s is a store, c is a county, and t is the month-year. The coefficient estimates the change 
in antacid market share with recreational access, where ����� denotes dispensary entry in county
c in month-year t. To control for county-level seasonality that occur from different patterns in 
tourism, we include county-month and county-year fixed effects. We include county-level
population, �����, to control for changes in the composition of demand related to migration. We
include the share of 2010 population enrolled in the medical marijuana program,����, to
control for changes in access to medical cannabis.  Standard errors are clustered by county.
For our category analysis, we interact recreational access to cannabis with indicator variables for
H2s and PPIs. Fixed effects are at the store-category level. Observations are for a store s, for
drug type d, in month-year t.�ℎ������ = �� + ����� + [����� ∗ �2�] + [����� ∗ ����] + ���� + �� + �� + ���� (2)
In both the store and store-category, we vary the window of the period of the analysis to ensure
our results are robust. We begin with the widest window, from 2013-2015, and narrow to seven
months before and after cannabis became recreationally legal, 5/2013-7/2014. In this last
sensitivity check with a restricted panel, we no longer have sufficient variation as to include




     
   
  
     
 
 









     
     
    
   
    
   
    
   
    
   
    
    
    





    
    
                                                 
         
      
  
  
   
    
 
We weight observations by the county’s population in 2014 using weighted least squares (WLS).
Weighting is justified if sampling is endogenous or the degree of intracluster correlation is low 
and the variance in the number of observations per cluster is high (Solon, Haider and Wooldridge
2015).  In our case, sampling may be endogenous because chain stores are overrepresented in the 
Nielsen data and independent stores may be more likely in less populous counties. We also
observe large variation in the number of observations per cluster. In these cases, WLS will 
increase efficiency.7 
In addition to our main specification, we estimate an event study specification to look for
pretrends and observe the temporal pattern of antacid sales after recreation access.  The 
specification we use is�ℎ����� = � + ∑6�=−6 � {��� = �} + �−1{��� −7} + �+1{���  7} + ���� + �� + �� + ��� (3)
The omitted category is the month before recreational dispensary entry. We plot the coefficients� , �− and �+ in Figure 2.
Table II: Antacids Market Share & Recreational Cannabis Access
(1) (2) (3)
2013-2015 2013-2014 5/2013-7/2014
Rec Dispensary -0.431*** -0.842*** -0.150**
(0.051) (0.060) (0.057)
Med Marijuana Share 0.636** 1.348*** 0.791**
(0.259) (0.461) (0.343)
Population -0.491 -0.858 -0.655
(0.704) (0.966) (0.801)
Constant 19.149** 22.327* 20.630*
(9.076) (12.443) (10.446)
Fixed Effects Store, CountyXMonth, CountyXYear Store, County, Year
Estimation Framework WLS WLS WLS
Observations 24,846 16,596 10,399
R-squared 0.861 0.865 0.868
Notes: Coefficients are measured in percentage points (0 to 100.) Clustered standard errors are in parentheses.
p<0.01 ***, p<0.05 **, p<0.1 *
3. Results
Our regression results in Table II suggest that cannabis acts as a substitute for OTC
antacids.8 Access to a dispensary initially decreased OTC antacid market share by 0.15 
7 In robustness checks, we estimated Tables II and III using OLS. WLS and OLS have different probability limits, 
making the comparison of the two a useful diagnostic for model misspecification (DuMouchel and Duncan 1983).
In our case, we see that the WLS estimates tend to be more precise, but the estimates are not very different,
suggesting that heteroscedasticity across counties is likely present.
8 The conclusions drawn from the Nielsen data are those of the researchers and do not reflect the views of Nielsen.




    
   
  
  
   
   
    
  
 








    
    
    
  









percentage points. Over the course of the year after recreational access, recreational dispensary
entry decreased antacid market share by 0.8 percentage points or 5.5%. If individuals travel
across county lines to obtain cannabis, we underestimate the effect.  The effect seems strongest
between six and twelve months after recreational access (column 2). If we extend the window
out to two years after legalization in Colorado, the magnitude of the effect decreases by about
half.  
Figure 2 plots coefficients from our event-study specification. We find no evidence that
our results are driven by a pre-trend. Instead, we see a dramatic decrease in the month of
dispensary entry.  Sales decrease sharply for the first three months, leveling out around a
decrease of 0.5 percentage points, which is close to the estimate in column 1 of Table II. This
pattern is also reflected in columns of Table II, where the decrease in market share is smaller
when estimated using the shorter panel, which weights the coefficient toward the effect in the 
first few months post-entry. 
Figure 2: Event Study of OTC Antacids Share Before and After First Dispensary
Counties with later dispensary entry, which help identify the effect in column one of Table II, 
seem to have a weaker substitution response; the coefficients are smaller than when we use the
2013-2014 sample. This may be because of spillovers, e.g. residents travel to nearby counties to
get access to cannabis without a prescription. Alternatively, conditional on the absence of a
county-wide ban, dispensaries may first enter markets with greater latent cannabis demand.
Table III indicates that decreased demand for H-2s and PPIs rather than acid neutralizers drives
the decrease in antacid market share. Dispensary entry decreases market share in 2014 by 1.3 
percentage points for H2 and 2.2 percentage points for PPIs.  These changes are in the range of
6-15%.  Recall that these classes of antacids are stronger and more effective than acid





     
     
    
   
    
   
    
   
    
   
    
   
    
   
    
    
    




   
     
  
 
    
  
     
 
   
    
   





    
   
 
   
                                                 
    
     
Table III: Antacids Market Share by Drug Type & Recreational Cannabis Access
(1) (2) (3)
2013-2015 2013-2014 5/2013-7/2014
Rec Dispensary 1.093*** 1.063*** 0.656***
(0.201) (0.206) (0.160)
Dispensary X H2 -1.262*** -1.334*** -0.898***
(0.354) (0.323) (0.236)
Dispensary X PPI -2.192*** -2.132*** -1.108***
(0.274) (0.273) (0.261)
Med Marijuana Share 0.038* 0.016 -0.037
(0.022) (0.027) (0.032)
Population 0.053 0.082** 0.011
(0.054) (0.036) (0.046)
Constant 33.223*** 32.864*** 33.891***
(0.675) (0.483) (0.578)
Fixed Effects Store, CountyXMonth, CountyXYear Store, County, Year
Estimation Framework WLS WLS WLS
Observations 74,568 49,845 31,197
R-squared 0.981 0.981 0.983
Notes: Coefficients are measured in percentage points (0 to 100.) Clustered standard errors are in parentheses.
p<0.01 ***, p<0.05 **, p<0.1 *
4. Discussion: Clinical link between Cannabis and GERD
To our knowledge, we are the first to show that recreational access to cannabis may 
substitute for the use of drugs that inhibit gastric acid secretion.  We propose two mechanisms
that could explain the link between cannabis and GERD symptom management. First, cannabis
may directly substitute for PPI and H-2s by reducing tightening of the lower esophageal
sphincter (Beaumont et al. 2009), mediating GI homeostasis (Abdel-Salam et al. 2015) or 
enhancing resolution of gastrointestinal (GI) tract inflammation (Wallace et al. 2013). Cannabis
inhibits stimulated gastric acid secretion and increases the secretion of gastric mucus, an 
important mucosal protective mechanism (Abdel-Salam et al., 2015).9 By decreasing gastric
acid secretion, subjects with GERD may experience fewer symptoms.  This would be consistent
with historical cannabis use for GI distress (Russo 2007), individual self-reports of such use
(Stith et al., 2018), and the approval of cannabis to treat severe nausea by state medical cannabis
programs. Since five out of six cannabis users consume for health as well as recreational
purposes (Pacula et al. 2016), a decrease in antacid use may occur in response to intentional
treatment of GERD symptoms or as a by-product from recreational or other medical use.
Alternatively, cannabis use may indirectly decrease antacid use by modifying dietary behaviors. 
The endocannabinoid system plays a major role in the brain-gut axis, regulating energy balance
through appetite control. Phytocannabinoid consumption excites the motivation to eat, visceral
satiety, and cravings for different types of macronutrients (Kirkham 2009), i.e., it is possible that 
9 For example, in a study on human subjects, Nalin et al. (1978) found that smoking cannabis for more than 2 days a




    
      
          
     








    
     
     
   
  
   
   
    
   
   
  
cannabis use may change the composition of food, drink, and medication consumed in ways that
may relieve GERD symptoms or GI distress.  Further supporting this conjecture, other studies
have found that medical cannabis access reduces consumption of alcohol (Anderson et al. 2013;
Baggio et al. 2017), a substance with a pro-oxidant effect on the gut-barrier (Hsu et al. 2015). 
Modification of dietary behaviors would be consistent with lower body mass after medical
access (Sabia et al. 2015), potentially due to down-regulation of CB1R, a cannabinoid receptor in
the brain associated with gastrointestinal activity (Di Marzo et al. 2001).   
5. Conclusion 
Using a natural experiment in Colorado, we demonstrate an overlooked, potential benefit from
recreational access to cannabis: off-label cannabis use. We focus on GERD, a common condition 
unlisted among state medical cannabis programs, but theoretically influenced by cannabis use. 
Dispensary entry decreased retailers’ antacid market share. We find no evidence that a pre-trend
drives our results. Decreases in acid-blocking medications risky for older adults drove the
decline. The clinical link between cannabis and GERD may occur through direct substitution of 
cannabis for OTC antacids, through changes in dietary behaviors that preclude antacid use, or
both.  More work is needed to disentangle these two effects as well as to identify appropriate
dosing and assess the likelihood of users developing a tolerance to cannabis’ effects.  More work
is also needed to quantify the risk-benefit tradeoffs between cannabis and conventional OTC
antacids, particularly among older adults for whom some conventional antacids can increase
morbidity. Spending on OTC antacids in 2014 would have decreased by $267 million given
nationwide recreational access.  Future work should assess clinical care benefits from
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